This from todays Seeking Alpha:
If things go to plan, Exact Sciences should be launching the Cologuard test about two years from now. As of the company's last report, there are 59 sites enrolling patients for its pivotal study, and another 20 or so should come online in the first quarter of 2012.
Assuming that the numbers of cancer in the enrollment population stay consistent, enrollment should finish in about six months. The company will then hope to announce results in the fourth quarter of 2012, submit its final clinical module to the FDA a quarter later, and receive FDA approval in 2014.
i've never been down that way . . . luckily this is as far as i had to retreat, lol . . .
there are 2 speck houses on the S2 just before saddleback, so i guessed . . .
check your spam, lol . . .
yes, i'll sell at 5.-
really?, a house on the S2? . . . is it one of those 2 for sale? . . . i'm NOT in "the hood", i'm at the dead end of a private road . . .
is your handle an e-mail account? . . .
$3.80 is a good price. sell at $5 opex though. Lawsuits/no sales/no FDA etc. imo. Don't listen to all the old Euclid/farrtker aliases
I too have a house on S2 and one in Julian, no mortgage on either. The earthquake thing came from lack of sales and realtors complaining. Nice and quiet there. In central Ca. we've gone from 1.2 mil to 800k
yup, but they renamed it shelter valley for some reason, lol . . . it goes from 25 to 80 to 25 degrees, and the wind often whips at 40 mph . . . shelter?, lol . . . the key is i own this place outright . . . the 460k house i gave back to the bank resold for 225K . . . i didn't walk away, i RAN away, lol . . . it is beautiful down here most of the time . . . if you like peace and quiet . . .
i added to my SQNM at 3.80, avg 4.20 . . . it'll come back . . . thanks for your concern . . .
That Seeking Alpha blogger made another mistake in addition to those you mentioned Sailing.. He suggested that the competitive landscape was due to Epigenomics using alternative methylation markers. What he neglected to mention is that those tests use blood rather than stool and are lousy at detectiing pre-cancers. The bigger problem, as discussed here before, is proving that a blood based marker test can outperform the much cheaper FIT - we know it doesn't beat stool. I would agree - a blogger with understanding about an inch deep, but at least he was positive and captured the general picture somewhat accurately. He also had a good line "biotech investors can never sleep on risk." Amen to that one.